Non-Human Primate (NHP) Oncology Model Development Service

Are you currently facing a long drug development cycle or challenges in validating therapeutic efficacy in a clinically relevant model? Creative Biolabs' NHP Oncology Model Development service helps you accelerate oncology drug discovery and streamline clinical trials by providing high-fidelity, translational disease models through advanced in situ gene-editing technology.

Overview of NHP Oncology Model Development

What Our Service Is

At Creative Biolabs, our NHP Oncology Model Development service provides highly sophisticated, translational disease models using NHPs. This service involves the precise, targeted induction of cancer within NHPs to create models that closely mimic the biology, pathology, and metastatic behavior of human malignancies. These models serve as a critical bridge between conventional preclinical studies and human clinical trials, offering unparalleled predictability for therapeutic outcomes. This service is a valuable tool for:

• Translational Drug Efficacy Testing: Validating the efficacy of novel anti-cancer drugs, immunotherapies, and combination therapies in a model that shares key genetic and immunological pathways with humans.
• Biomarker Discovery and Validation: Identifying and validating novel biomarkers for patient stratification, treatment response prediction, and drug resistance.
• Medical Device and Procedure Development: Testing and refining surgical techniques or medical devices designed for oncology applications.

Why Choose Us?

The development of oncology drugs has long been challenged by the lack of predictive preclinical models. While rodent models are useful, their genetic, physiological, and immunological differences from humans often lead to failures in clinical trials. Creative Biolabs addresses this critical pain point by providing highly translational NHP models.

• Reducing Clinical Trial Risk: By using models that more accurately reflect human disease, we provide data that can increase the probability of success in clinical trials.
• Accelerating Development Timelines: The high-fidelity of our models enables more confident and rapid decision-making, significantly shortening the time from discovery to clinical validation.
• Generating Clinically Relevant Insights: Our models allow for the study of drug effects on human-like tumor microenvironments, metastasis, and the complex interplay with the immune system.

Fig.1 Development of an in situ gene-editing technique for swiftly modeling primary and metastatic liver tumors in adult cynomolgus monkeys.¹

Key Benefits of Our Service

Creative Biolabs' NHP Oncology Model Development service offers a strategic advantage for your research. Our models, whether spontaneous or induced, exhibit a level of translational relevance that is unmatched in the field. Our in-house expertise and robust infrastructure allow for rapid and precise model generation.

• Rapid Response: We can typically initiate studies within two weeks, ensuring your research timeline stays on track.
• Extensive NHP Resources: Our large, on-site facilities can accommodate a broad range of NHP species, which including but not limited to Cynomolgus, Rhesus, Marmoset, and African Green Monkey.
• Unmatched Customization: We offer bespoke model development to specifically address the unique needs of your research project, including the ability to model a wide range of human tumor types.
• In-Depth Reporting: Our comprehensive reports provide not just raw data, but also in-depth analysis, including histopathology, biomarker detection, and pharmacodynamic insights.

How Creative Biolabs' NHP Model Development Can Assist Your Project?

Creative Biolabs' NHP Oncology Model Development service delivers concrete, actionable solutions to your most pressing challenges. Our models provide a robust platform for evaluating drug efficacy, safety, and pharmacokinetics in a system that more accurately predicts human outcomes.

Key Deliverables

Our commitment to excellence is reflected in the quality of our deliverables, which include:

• A comprehensive, publication-quality lab report.
• All raw data and analyzed datasets (e.g., tumor growth curves, PK/PD data).
• Detailed histopathological slides with annotations.
• Digital images and videos of tumors and other key observations.

Capabilities & Partnerships

Service-Specific Data

• Annual Sample Size: Over 50,000 samples analyzed per year.
• Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
• Study Pass Rate: 99%+ success rate in meeting study endpoints.

Our Valued Partners

Frequently Asked Questions

Contact Us

Creative Biolabs is your trusted partner in accelerating oncology drug discovery. Our NHP Oncology Model Development service, powered by state-of-the-art technology and extensive expertise, provides the high-fidelity, translational models you need to confidently move your therapeutic from the lab to the clinic. To learn more about our NHP oncology models and discuss how we can support your specific project, please reach out to our dedicated team.